Real-world response to immune checkpoint inhibitors (ICIs) may be poorer than outcomes reported in pivotal clinical trials, according to results from a Veterans Affairs study of nearly 12,000 cancer patients with a mix of demographic and clinical characteristics.
Overall, “patients receiving ICIs appear to have worse survival than patients in the corresponding [pivotal clinical trials],” reported Jennifer La, PhD, a data scientist at VA Boston Healthcare System, and her